Close

PureTech Health (PRTC) Entity Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA

Go back to PureTech Health (PRTC) Entity Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA

PureTech Founded Entity Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA

October 5, 2021 8:01 AM EDT

High-dose VE303 in Phase 2 trial achieved primary endpoint, with 31.7% absolute risk reduction in rate of recurrence (or a greater than 80% reduction in the odds of a recurrence) at 8 weeks when compared with placebo

Represents most advanced clinical trial of a rationally defined bacterial consortium candidate

BARDA exercises $23.8 million option to support Phase 3 clinical trial of VE303, to initiate in 2022

BOSTON--(BUSINESS... More